Health Care [ 4/12 ] | Biotechnology [ 11/75 ]
NASDAQ | Common Stock
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally.
The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism.
It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.
The company was incorporated in 2006 and is based in Hellerup, Denmark.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 11, 26 | -0.55 Increased by +14.06% | -0.15 Decreased by -266.67% |
| Nov 6, 25 | -1.00 Increased by +41.86% | -0.28 Decreased by -257.14% |
| Aug 7, 25 | -0.64 Increased by +69.67% | -1.31 Increased by +51.15% |
| May 1, 25 | -1.58 Increased by +31.30% | -1.51 Decreased by -4.64% |
| Feb 12, 25 | -0.64 Increased by +58.44% | -0.93 Increased by +31.18% |
| Nov 14, 24 | -1.72 Increased by +40.28% | -1.49 Decreased by -15.44% |
| Sep 3, 24 | -2.11 Increased by +2.31% | -1.46 Decreased by -44.52% |
| May 2, 24 | -2.30 Decreased by -16.16% | -1.50 Decreased by -53.33% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 245.18 M Increased by +40.98% | -33.25 M Increased by +13.57% | Decreased by -13.56% Increased by +38.69% |
| Sep 30, 25 | 213.63 M Increased by +269.40% | -60.99 M Increased by +38.52% | Decreased by -28.55% Increased by +83.36% |
| Jun 30, 25 | 158.04 M Increased by +339.04% | -38.85 M Increased by +64.48% | Decreased by -24.58% Increased by +91.91% |
| Mar 31, 25 | 100.95 M Increased by +5.28% | -94.63 M Increased by +27.79% | Decreased by -93.73% Increased by +31.41% |
| Dec 31, 24 | 173.92 M Increased by +26.30% | -38.47 M Increased by +55.72% | Decreased by -22.12% Increased by +64.94% |
| Sep 30, 24 | 57.83 M Increased by +20.40% | -99.20 M Increased by +38.85% | Decreased by -171.52% Increased by +49.21% |
| Jun 30, 24 | 36.00 M Decreased by -24.04% | -109.38 M Increased by +9.93% | Decreased by -303.85% Decreased by -18.59% |
| Mar 31, 24 | 95.89 M Increased by +185.49% | -131.03 M Decreased by -18.14% | Decreased by -136.65% Increased by +58.62% |